Compare Mesoblast Limited (MESO) vs Xcel Energy Inc (XEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Xcel Energy Inc — how do they compare? Mesoblast Limited trades at $16.87 (market cap $2.21B), while Xcel Energy Inc trades at $77.99 (market cap $48.51B). The key difference: Xcel Energy Inc is far larger — about 22× Mesoblast Limited's market cap, and Xcel Energy Inc pays a 3.05% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | XEL | |
|---|---|---|
Market Cap | $2.21B | $48.51B |
Sector | Technology | Utilities |
52-Week High | $20.96 | $83.91 |
52-Week Low | $12.88 | $71.75 |
Enterprise Value | $2.21B | $86.82B |
Dividend Yield | — | 3.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.9, up 1.32% on the day, with a bullish technical signal from moving averages. The company reported Ryoncil net revenues of $36 million for the quarter ended June 30, 2026, and achieved its target of 300 patients in a Phase 3 trial for chronic low back pain. Despite strong revenue growth from its commercial launch, fundamentals show a net income margin of -144.33% and negative EBITDA of $80.06 million for 2025, reflecting significant losses amid expansion.
The outlook hinges on commercial execution and regulatory progress, with analyst consensus leaning buy (45% buy ratings). Key risks include high cash burn, dependence on pipeline success, and competitive pressures. Upside potential exists if revenue growth accelerates and losses narrow, but investors face volatility from clinical trial outcomes and funding needs.
Xcel Energy (XEL) trades at $76.87, down 1.54% on the day, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $0.93 per share, beating estimates, and maintains a solid dividend. Revenue for 2025 was $14.67 billion with a net income margin of 15.28%, while analyst consensus is bullish with a $93.80 price target.
The outlook is supported by earnings growth and a $60 billion capital investment plan, but risks include regulatory pushback and high debt levels. The stock offers a stable investment opportunity with growth potential from infrastructure spending, though affordability concerns and interest rate sensitivity pose challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Xcel Energy Inc
Xcel Energy manages utilities serving 3.7 million electric customers and 2.1 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan
Read more on XEL →
